Proportional impairment ratio calculation formula for an antihistamine.

Central Nervous System Effects of the Second-Generation Antihistamines Marketed in Japan -Review of Inter-Drug Differences Using the Proportional Impairment Ratio (PIR)-

Tatsuya Isomura (548724)
Takeshi Kono (674097)
Ian Hindmarch (674098)
Norimasa Kikuchi (462989)
Aya Murakami (432768)
Kyoko Inuzuka (548725)
Seiji Kawana (674099)

December 2014

<div>BackgroundSecond-generation antihistamines (AHs) have, in general, fewer sedative eff...

HPV 31/33/45: Prevalence ratio employed for calculating direct, indirect, total and overall effectiveness.

M. Jesus Purriños-Hermida (5593646)
María Isolina Santiago-Pérez (5593649)
Mercedes Treviño (5593652)
Rafaela Dopazo (5593655)
Angelina Cañizares (667514)
Isolina Bonacho (5593658)
Matilde Trigo (830322)
M. Eva Fernández (5593661)
Ana Cid (612956)
David Gómez (5593664)
Patricia Ordóñez (830317)
Amparo Coira (5593667)
M. J. Armada (5593670)
Magdalena Porto (5593673)
Sonia Perez (3460616)
Alberto Malvar-Pintos (5593676)

August 2018

HPV 31/33/45: Prevalence ratio employed for calculating direct, indirect, total and overall effec...

Proportion of medicines with significant dips in consumption, by disease and quarter.

Ninell Kadyrova (17598812)
Dzintars Gotham (3536519)
Stanislav Kniazkov (17460414)
Elsever Aghayev (17598815)
Polad Hajibalayev (17598818)
Zohid Ermatov (17598821)
Natasha Azzopardi Muscat (17598824)

December 2023

Proportion of medicines with significant dips in consumption, by disease and quarter.</p

Calculation of proportional impairment ratio for objective tests by dose.

Tatsuya Isomura (548724)
Takeshi Kono (674097)
Ian Hindmarch (674098)
Norimasa Kikuchi (462989)
Aya Murakami (432768)
Kyoko Inuzuka (548725)
Seiji Kawana (674099)

December 2014

a: Number of tests showing ‘impairment’ with the named antihistamine (AH). b: Number of tests sho...

Calculation of proportional impairment ratio for subjective tests for the second-generation antihistamines in Japan.

Tatsuya Isomura (548724)
Takeshi Kono (674097)
Ian Hindmarch (674098)
Norimasa Kikuchi (462989)
Aya Murakami (432768)
Kyoko Inuzuka (548725)
Seiji Kawana (674099)

December 2014

a: Number of tests showing ‘impairment’ with the named antihistamine (AH). b: Number of tests sho...

Number of test results showing impairment and no impairment for each AH by dose.

Tatsuya Isomura (548724)
Takeshi Kono (674097)
Ian Hindmarch (674098)
Norimasa Kikuchi (462989)
Aya Murakami (432768)
Kyoko Inuzuka (548725)
Seiji Kawana (674099)

December 2014

Number of test results showing impairment and no impairment for each AH by dose.</p

Compared to mosquitoes fed with 0ng/ml ivermectin, the reduction degree of infection rate for each treatment group.

Tie-Long Xu (5987963)
Yin Han (5987966)
Wei Liu (20030)
Xing-Ya Pang (5987969)
Bin Zheng (45359)
Yi Zhang (9093)
Xiao-Nong Zhou (92570)

December 2018

The calculation formula is as follows: (infection rate in mosquitoes fed with 0ng/ml ivermectin-infe...

Superiority of the F3 over the NH36 vaccine.

Dirlei Nico (359890)
Carla Claser (185910)
Gulnara P. Borja-Cabrera (359891)
Luiz R. Travassos (92355)
Marcos Palatnik (359893)
Irene da Silva Soares (359894)
Mauricio Martins Rodrigues (5653378)
Clarisa B. Palatnik-de-Sousa (359896)

February 2013

Calculation was performed according the following equation = (F3-NH36/F3) values x 100 = prote...

The number of all-cause hospitalizations and proportion of hospitalizations for clinicaly diagnosed influenza and laboratory-confirmed influenza.

Yuriko Hagiwara (13899438)
Kazumasa Harada (426929)
Joshua Nealon (2993298)
Yasuyuki Okumura (3079893)
Takeshi Kimura (159578)
Sandra S. Chaves (7377869)

October 2022

The percentage refers to the number of clinically diagnosed influenza and laboratory-confirmed influ...

Number and percentages of subjects showing adverse events after administration of drugs in different treatment arms.

Shantanu Kumar Kar (704077)
Bhagirathi Dwibedi (704078)
Anna Salomi Kerketa (704079)
Antaryami Maharana (704080)
Sudanshu S Panda (704081)
Prafulla Chandra Mohanty (704082)
John Horton (218580)
Cherubala P Ramachandran (704083)

March 2015

Number and percentages of subjects showing adverse events after administration of drugs in differ...

Antibiotics in patients.

Anne Mette Lerbech (668321)
Japheth A. Opintan (161817)
Samuel Oppong Bekoe (668322)
Mary-Anne Ahiabu (668323)
Britt Pinkowski Tersbøl (668324)
Martin Hansen (668325)
Kennedy T. C. Brightson (668326)
Samuel Ametepeh (668327)
Niels Frimodt-Møller (68909)
Bjarne Styrishave (668328)

December 2014

A: Percentage of patients relative to the number of antibiotics to which isolates exhibited resis...

The number of compounds found to demonstrate inhibition at 10μM overall and with respect to the two different methods of ranking compounds.

David Ryan Koes (781765)
Nicolas A. Pabon (781766)
Xiaoyi Deng (781767)
Margaret A. Phillips (270292)
Carlos J. Camacho (179401)

August 2015

The number of compounds found to demonstrate inhibition at 10μM overall and with respect to the t...

Hazard ratio according to number of previous periods of sickness absence regardless of cause for the total sample and stratified for gender.

Liesbeth E. C. Wijnvoord (2805259)
Sandra Brouwer (840928)
Jan Buitenhuis (292897)
Jac J. L. van der Klink (444147)
Michiel R. de Boer (840929)

May 2016

Hazard ratio according to number of previous periods of sickness absence regardless of cause for ...

The frequency of acute toxicities for the three groups [No. of patient (%)].

Jianshe Wang (730385)
Junnian Zheng (283838)
Tianyou Tang (730386)
Feng Zhu (685)
Yuanhu Yao (730387)
Jing Xu (15337)
Andrew Z. Wang (730388)
Longzhen Zhang (730389)

April 2015

The frequency of acute toxicities for the three groups [No. of patient (%)].</p

Calculated hazard ratios of dementia (Alzheimer’s and vascular) in the AS and control groups.

Hae-Dong Jang (4183555)
Jin-Sung Park (218422)
Dae Woong Kim (821776)
Kyungdo Han (507253)
Byung-Joon Shin (4183558)
Jae Chul Lee (1310067)
Sung-Woo Choi (4183561)
Seung-Woo Suh (4183570)
Jae-Hyuk Yang (4183567)
Si-Young Park (740102)
Whi Je Cho (6281555)
Jae-Young Hong (3175941)

January 2019

Calculated hazard ratios of dementia (Alzheimer’s and vascular) in the AS and control groups.</p

Central Nervous System Effects of the Second-Generation Antihistamines Marketed in Japan -Review of Inter-Drug Differences Using the Proportional Impairment Ratio (PIR)-

Tatsuya Isomura (548724)
Takeshi Kono (674097)
Ian Hindmarch (674098)
Norimasa Kikuchi (462989)
Aya Murakami (432768)
Kyoko Inuzuka (548725)
Seiji Kawana (674099)

December 2014

<div>BackgroundSecond-generation antihistamines (AHs) have, in general, fewer sedative eff...

HPV 31/33/45: Prevalence ratio employed for calculating direct, indirect, total and overall effectiveness.

M. Jesus Purriños-Hermida (5593646)
María Isolina Santiago-Pérez (5593649)
Mercedes Treviño (5593652)
Rafaela Dopazo (5593655)
Angelina Cañizares (667514)
Isolina Bonacho (5593658)
Matilde Trigo (830322)
M. Eva Fernández (5593661)
Ana Cid (612956)
David Gómez (5593664)
Patricia Ordóñez (830317)
Amparo Coira (5593667)
M. J. Armada (5593670)
Magdalena Porto (5593673)
Sonia Perez (3460616)
Alberto Malvar-Pintos (5593676)

August 2018

HPV 31/33/45: Prevalence ratio employed for calculating direct, indirect, total and overall effec...

Proportion of medicines with significant dips in consumption, by disease and quarter.

Ninell Kadyrova (17598812)
Dzintars Gotham (3536519)
Stanislav Kniazkov (17460414)
Elsever Aghayev (17598815)
Polad Hajibalayev (17598818)
Zohid Ermatov (17598821)
Natasha Azzopardi Muscat (17598824)

December 2023

Proportion of medicines with significant dips in consumption, by disease and quarter.</p

Calculation of proportional impairment ratio for objective tests by dose.

Tatsuya Isomura (548724)
Takeshi Kono (674097)
Ian Hindmarch (674098)
Norimasa Kikuchi (462989)
Aya Murakami (432768)
Kyoko Inuzuka (548725)
Seiji Kawana (674099)

December 2014

a: Number of tests showing ‘impairment’ with the named antihistamine (AH). b: Number of tests sho...

Calculation of proportional impairment ratio for subjective tests for the second-generation antihistamines in Japan.

Tatsuya Isomura (548724)
Takeshi Kono (674097)
Ian Hindmarch (674098)
Norimasa Kikuchi (462989)
Aya Murakami (432768)
Kyoko Inuzuka (548725)
Seiji Kawana (674099)

December 2014

a: Number of tests showing ‘impairment’ with the named antihistamine (AH). b: Number of tests sho...

Number of test results showing impairment and no impairment for each AH by dose.

Tatsuya Isomura (548724)
Takeshi Kono (674097)
Ian Hindmarch (674098)
Norimasa Kikuchi (462989)
Aya Murakami (432768)
Kyoko Inuzuka (548725)
Seiji Kawana (674099)

December 2014

Number of test results showing impairment and no impairment for each AH by dose.</p

Compared to mosquitoes fed with 0ng/ml ivermectin, the reduction degree of infection rate for each treatment group.

Tie-Long Xu (5987963)
Yin Han (5987966)
Wei Liu (20030)
Xing-Ya Pang (5987969)
Bin Zheng (45359)
Yi Zhang (9093)
Xiao-Nong Zhou (92570)

December 2018

The calculation formula is as follows: (infection rate in mosquitoes fed with 0ng/ml ivermectin-infe...

Superiority of the F3 over the NH36 vaccine.

Dirlei Nico (359890)
Carla Claser (185910)
Gulnara P. Borja-Cabrera (359891)
Luiz R. Travassos (92355)
Marcos Palatnik (359893)
Irene da Silva Soares (359894)
Mauricio Martins Rodrigues (5653378)
Clarisa B. Palatnik-de-Sousa (359896)

February 2013

Calculation was performed according the following equation = (F3-NH36/F3) values x 100 = prote...

The number of all-cause hospitalizations and proportion of hospitalizations for clinicaly diagnosed influenza and laboratory-confirmed influenza.

Yuriko Hagiwara (13899438)
Kazumasa Harada (426929)
Joshua Nealon (2993298)
Yasuyuki Okumura (3079893)
Takeshi Kimura (159578)
Sandra S. Chaves (7377869)

October 2022

The percentage refers to the number of clinically diagnosed influenza and laboratory-confirmed influ...

Number and percentages of subjects showing adverse events after administration of drugs in different treatment arms.

Shantanu Kumar Kar (704077)
Bhagirathi Dwibedi (704078)
Anna Salomi Kerketa (704079)
Antaryami Maharana (704080)
Sudanshu S Panda (704081)
Prafulla Chandra Mohanty (704082)
John Horton (218580)
Cherubala P Ramachandran (704083)

March 2015

Number and percentages of subjects showing adverse events after administration of drugs in differ...

Antibiotics in patients.

Anne Mette Lerbech (668321)
Japheth A. Opintan (161817)
Samuel Oppong Bekoe (668322)
Mary-Anne Ahiabu (668323)
Britt Pinkowski Tersbøl (668324)
Martin Hansen (668325)
Kennedy T. C. Brightson (668326)
Samuel Ametepeh (668327)
Niels Frimodt-Møller (68909)
Bjarne Styrishave (668328)

December 2014

A: Percentage of patients relative to the number of antibiotics to which isolates exhibited resis...

The number of compounds found to demonstrate inhibition at 10μM overall and with respect to the two different methods of ranking compounds.

David Ryan Koes (781765)
Nicolas A. Pabon (781766)
Xiaoyi Deng (781767)
Margaret A. Phillips (270292)
Carlos J. Camacho (179401)

August 2015

The number of compounds found to demonstrate inhibition at 10μM overall and with respect to the t...

Hazard ratio according to number of previous periods of sickness absence regardless of cause for the total sample and stratified for gender.

Liesbeth E. C. Wijnvoord (2805259)
Sandra Brouwer (840928)
Jan Buitenhuis (292897)
Jac J. L. van der Klink (444147)
Michiel R. de Boer (840929)

May 2016

Hazard ratio according to number of previous periods of sickness absence regardless of cause for ...

The frequency of acute toxicities for the three groups [No. of patient (%)].

Jianshe Wang (730385)
Junnian Zheng (283838)
Tianyou Tang (730386)
Feng Zhu (685)
Yuanhu Yao (730387)
Jing Xu (15337)
Andrew Z. Wang (730388)
Longzhen Zhang (730389)

April 2015

The frequency of acute toxicities for the three groups [No. of patient (%)].</p

Calculated hazard ratios of dementia (Alzheimer’s and vascular) in the AS and control groups.

Hae-Dong Jang (4183555)
Jin-Sung Park (218422)
Dae Woong Kim (821776)
Kyungdo Han (507253)
Byung-Joon Shin (4183558)
Jae Chul Lee (1310067)
Sung-Woo Choi (4183561)
Seung-Woo Suh (4183570)
Jae-Hyuk Yang (4183567)
Si-Young Park (740102)
Whi Je Cho (6281555)
Jae-Young Hong (3175941)

January 2019

Calculated hazard ratios of dementia (Alzheimer’s and vascular) in the AS and control groups.</p

Central Nervous System Effects of the Second-Generation Antihistamines Marketed in Japan -Review of Inter-Drug Differences Using the Proportional Impairment Ratio (PIR)-

Tatsuya Isomura (548724)
Takeshi Kono (674097)
Ian Hindmarch (674098)
Norimasa Kikuchi (462989)
Aya Murakami (432768)
Kyoko Inuzuka (548725)
Seiji Kawana (674099)

December 2014

<div>BackgroundSecond-generation antihistamines (AHs) have, in general, fewer sedative eff...

HPV 31/33/45: Prevalence ratio employed for calculating direct, indirect, total and overall effectiveness.

M. Jesus Purriños-Hermida (5593646)
María Isolina Santiago-Pérez (5593649)
Mercedes Treviño (5593652)
Rafaela Dopazo (5593655)
Angelina Cañizares (667514)
Isolina Bonacho (5593658)
Matilde Trigo (830322)
M. Eva Fernández (5593661)
Ana Cid (612956)
David Gómez (5593664)
Patricia Ordóñez (830317)
Amparo Coira (5593667)
M. J. Armada (5593670)
Magdalena Porto (5593673)
Sonia Perez (3460616)
Alberto Malvar-Pintos (5593676)

August 2018

HPV 31/33/45: Prevalence ratio employed for calculating direct, indirect, total and overall effec...

Proportion of medicines with significant dips in consumption, by disease and quarter.

Ninell Kadyrova (17598812)
Dzintars Gotham (3536519)
Stanislav Kniazkov (17460414)
Elsever Aghayev (17598815)
Polad Hajibalayev (17598818)
Zohid Ermatov (17598821)
Natasha Azzopardi Muscat (17598824)

December 2023

Proportion of medicines with significant dips in consumption, by disease and quarter.</p

Proportional impairment ratio calculation formula for an antihistamine.

Abstract

Extracted data

Proportional impairment ratio calculation formula for an antihistamine.

Abstract

Extracted data

Related items

Related items